Broadly neutralizing antibody targeting the ebolavirus glycoprotein internal fusion loop

US11186626B2 · kind B2 · utility

Assignees

• INTEGRATED BIOTHERAPEUTICS, INC. · US
• UNIVERSITY OF MARYLAND, COLLEGE PARK · US

Inventors

• Mohammad Javad Aman · Rockville, US
• Katie A. Howell · North Bethesda, US
• Frederick Wayne Holtsberg · Rockville, US
• Xuelian Zhao · Tianjin, CN
• Yuxing Li · Boyds, US

Key dates

• Filing date: Oct 9, 2017
• Grant date: Nov 30, 2021
• Expiry date: Oct 9, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/14222
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This disclosure provides a method for preventing, treating, or managing an ebolavirus infection in a subject, where the method includes administering to a subject in need thereof an effective amount of at least one pan-ebolavirus internal fusion loop antibody or antigen-binding fragment thereof, wherein the binding domain specifically binds to the epitope on two or more ebolavirus species or strains.